FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296468429> ?p ?o ?g. }

• W4296468429 endingPage "S265" @default.
• W4296468429 startingPage "S264" @default.
• W4296468429 abstract "Minimal residual disease (MRD) is a predictive marker for progression-free survival (PFS) in chronic leukocytic leukemia (CLL) following chemoimmunotherapy and fixed-duration treatment with venetoclax and anti-CD20 antibodies. This has not been explored for ibrutinib+venetoclax (Ibr+Ven), a fixed-duration treatment with mechanisms of action that synergistically eliminate CLL subpopulations in distinct tumor compartments.Investigate MRD outcomes at primary analysis of phase 3 GLOW study (NCT03462719).Randomized, open-label, active-control study.Patients aged ≥65 years or 18-64 years with a CIRS score >6 or creatinine clearance <70 mL/min were randomized 1:1, stratified by IGHV mutational and del11q status, to Ibr+Ven (n=106) or chlorambucil+obinutuzumab (Clb+O) (n=105). Excluded: patients with del17p or known TP53 mutations.Ibr+Ven (3 cycles of ibrutinib lead-in, then 12 cycles of Ibr+Ven) or 6 cycles of Clb+O.Primary endpoint: independent review committee-assessed PFS; secondary endpoint: rate of undetectable MRD (uMRD; <10-4); exploratory endpoints: MRD analyses. MRD results are by next-generation sequencing, reported 3 months after end of treatment (EOT+3) unless otherwise noted.Rates of uMRD<10-4 were higher for Ibr+Ven versus Clb+O in bone marrow (BM) (51.9% vs. 17.1%; P<0.0001) and peripheral blood (PB) (54.7% vs. 39.0%; P=0.0259). For Ibr+Ven, BM uMRD was higher for uIGHV (58.2%) versus mutated IGHV (44.4%). With Ibr+Ven, 84.5% (49/58) of patients maintained PB uMRD from EOT+3 to EOT+12 versus 29.3% (12/41) with Clb+O. Rates of uMRD<10-5 were higher for Ibr+Ven versus Clb+O in BM (40.6% vs. 7.6%), including patients with uIGHV (45.5% vs. 5.6%). uMRD<10-5 in PB was largely sustained from EOT+3 to EOT+12 with Ibr+Ven (80.4% [37/46]) but not Clb+O (26.3% [5/19]). PFS rates for Ibr+Ven during the 12 months after EOT were >90% for patients with uMRD<10-4 and patients with detectable MRD; however, Clb+O arm patients with detectable PB MRD relapsed more quickly than those with uMRD<10-4.All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that were deeper and better sustained post-treatment versus Clb+O in older adult or unfit patients with previously untreated CLL." @default.
• W4296468429 created "2022-09-21" @default.
• W4296468429 creator A5000372371 @default.
• W4296468429 creator A5004217461 @default.
• W4296468429 creator A5012590429 @default.
• W4296468429 creator A5013649293 @default.
• W4296468429 creator A5016818736 @default.
• W4296468429 creator A5018055042 @default.
• W4296468429 creator A5026238093 @default.
• W4296468429 creator A5030896087 @default.
• W4296468429 creator A5034997188 @default.
• W4296468429 creator A5036887669 @default.
• W4296468429 creator A5046837534 @default.
• W4296468429 creator A5049924304 @default.
• W4296468429 creator A5056554686 @default.
• W4296468429 creator A5057884204 @default.
• W4296468429 creator A5059772145 @default.
• W4296468429 creator A5064164625 @default.
• W4296468429 creator A5065041441 @default.
• W4296468429 creator A5066337435 @default.
• W4296468429 creator A5069303553 @default.
• W4296468429 creator A5077089081 @default.
• W4296468429 creator A5077793241 @default.
• W4296468429 creator A5087571749 @default.
• W4296468429 date "2022-10-01" @default.
• W4296468429 modified "2023-09-27" @default.
• W4296468429 title "CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study" @default.
• W4296468429 doi "https://doi.org/10.1016/s2152-2650(22)01322-2" @default.
• W4296468429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36163867" @default.
• W4296468429 hasPublicationYear "2022" @default.
• W4296468429 type Work @default.
• W4296468429 citedByCount "0" @default.
• W4296468429 crossrefType "journal-article" @default.
• W4296468429 hasAuthorship W4296468429A5000372371 @default.
• W4296468429 hasAuthorship W4296468429A5004217461 @default.
• W4296468429 hasAuthorship W4296468429A5012590429 @default.
• W4296468429 hasAuthorship W4296468429A5013649293 @default.
• W4296468429 hasAuthorship W4296468429A5016818736 @default.
• W4296468429 hasAuthorship W4296468429A5018055042 @default.
• W4296468429 hasAuthorship W4296468429A5026238093 @default.
• W4296468429 hasAuthorship W4296468429A5030896087 @default.
• W4296468429 hasAuthorship W4296468429A5034997188 @default.
• W4296468429 hasAuthorship W4296468429A5036887669 @default.
• W4296468429 hasAuthorship W4296468429A5046837534 @default.
• W4296468429 hasAuthorship W4296468429A5049924304 @default.
• W4296468429 hasAuthorship W4296468429A5056554686 @default.
• W4296468429 hasAuthorship W4296468429A5057884204 @default.
• W4296468429 hasAuthorship W4296468429A5059772145 @default.
• W4296468429 hasAuthorship W4296468429A5064164625 @default.
• W4296468429 hasAuthorship W4296468429A5065041441 @default.
• W4296468429 hasAuthorship W4296468429A5066337435 @default.
• W4296468429 hasAuthorship W4296468429A5069303553 @default.
• W4296468429 hasAuthorship W4296468429A5077089081 @default.
• W4296468429 hasAuthorship W4296468429A5077793241 @default.
• W4296468429 hasAuthorship W4296468429A5087571749 @default.
• W4296468429 hasConcept C126322002 @default.
• W4296468429 hasConcept C143998085 @default.
• W4296468429 hasConcept C168563851 @default.
• W4296468429 hasConcept C203092338 @default.
• W4296468429 hasConcept C2776694085 @default.
• W4296468429 hasConcept C2776755627 @default.
• W4296468429 hasConcept C2777607594 @default.
• W4296468429 hasConcept C2777609679 @default.
• W4296468429 hasConcept C2777866208 @default.
• W4296468429 hasConcept C2777938653 @default.
• W4296468429 hasConcept C2778461978 @default.
• W4296468429 hasConcept C2779675984 @default.
• W4296468429 hasConcept C2779823535 @default.
• W4296468429 hasConcept C2779878957 @default.
• W4296468429 hasConcept C71924100 @default.
• W4296468429 hasConcept C90924648 @default.
• W4296468429 hasConceptScore W4296468429C126322002 @default.
• W4296468429 hasConceptScore W4296468429C143998085 @default.
• W4296468429 hasConceptScore W4296468429C168563851 @default.
• W4296468429 hasConceptScore W4296468429C203092338 @default.
• W4296468429 hasConceptScore W4296468429C2776694085 @default.
• W4296468429 hasConceptScore W4296468429C2776755627 @default.
• W4296468429 hasConceptScore W4296468429C2777607594 @default.
• W4296468429 hasConceptScore W4296468429C2777609679 @default.
• W4296468429 hasConceptScore W4296468429C2777866208 @default.
• W4296468429 hasConceptScore W4296468429C2777938653 @default.
• W4296468429 hasConceptScore W4296468429C2778461978 @default.
• W4296468429 hasConceptScore W4296468429C2779675984 @default.
• W4296468429 hasConceptScore W4296468429C2779823535 @default.
• W4296468429 hasConceptScore W4296468429C2779878957 @default.
• W4296468429 hasConceptScore W4296468429C71924100 @default.
• W4296468429 hasConceptScore W4296468429C90924648 @default.
• W4296468429 hasLocation W42964684291 @default.
• W4296468429 hasLocation W42964684292 @default.
• W4296468429 hasOpenAccess W4296468429 @default.
• W4296468429 hasPrimaryLocation W42964684291 @default.
• W4296468429 hasRelatedWork W1809182350 @default.
• W4296468429 hasRelatedWork W2204827588 @default.
• W4296468429 hasRelatedWork W2586959316 @default.
• W4296468429 hasRelatedWork W2794302045 @default.
• W4296468429 hasRelatedWork W2902300122 @default.
• W4296468429 hasRelatedWork W2967600517 @default.
• W4296468429 hasRelatedWork W4309787431 @default.

• next